SEC Form 4/A · accession 0001179110-19-002193
HALOZYME THERAPEUTICS, INC. · HALO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Dimitrios Chondros
Officer — SVP, Chief Medical Officer
Period of report
Feb 3, 2019
Accepted (ET)
Feb 20, 2019 · 8:10 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001159036
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 3, 2019 | S | 2,536 | $16.41 | D | 31,566 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On February 5, 2019, the reporting person filed a Form 4 reporting the disposition of 2,503 shares at a price of $16.12 per share representing the shares that were sold to pay minimum statutory tax withholding obligations due upon vesting of 6,165 restricted stock award shares. This report is being filed to correct the transaction code, the total number of shares sold, the price per share received upon disposition and the aggregate beneficial ownership of the reporting person as of February 3, 2019, which will be updated in Forms 4 filed after the date of this amendment.